Patents by Inventor David E. Fisher

David E. Fisher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11478607
    Abstract: Ureteral or bladder catheters are provided, including (a) a proximal portion; and (b) a distal portion, the distal portion including a retention portion that includes one or more protected drainage holes, ports or perforations and is configured to establish an outer periphery or protective surface area that inhibits mucosal tissue from occluding the one or more protected drainage holes, ports or perforations upon application of negative pressure through the catheter. Systems, kits and methods for inducing negative pressure to increase renal function also are provided.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: October 25, 2022
    Inventors: John R. Erbey, II, Jacob L. Upperco, David E. Orr, Michael Alan Fisher, Patrick William Strane, Lance Michael Black
  • Patent number: 11471583
    Abstract: A method for removing excess fluid from a patient with hemodilution is provided. The method includes: deploying a urinary tract catheter into the patient such that flow of urine from the ureter and/or kidney is transported within a drainage lumen of the catheter; applying negative pressure to the ureter and/or kidney through the drainage lumen of the catheter to extract urine from the patient; periodically measuring a hematocrit value of the patient; and if the measured hematocrit value is greater than a predetermined threshold value, ceasing the application of the negative pressure to the ureter and/or kidney. A system for removing excess fluid from a patient with hemodilution including a ureteral catheter and a pump is also provided.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: October 18, 2022
    Inventors: John R. Erbey, II, Jacob L. Upperco, Michael Alan Fisher, Patrick William Strane, Lance Michael Black, David E. Orr
  • Patent number: 11433217
    Abstract: Ureteral or bladder catheters are provided, including (a) a proximal portion; and (b) a distal portion, the distal portion including a retention portion that includes one or more protected drainage holes, ports or perforations and is configured to establish an outer periphery or protective surface area that inhibits mucosal tissue from occluding the one or more protected drainage holes, ports or perforations upon application of negative pressure through the catheter. Systems, kits and methods for inducing negative pressure to increase renal function also are provided.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: September 6, 2022
    Inventors: John R. Erbey, II, Jacob L. Upperco, David E. Orr, Michael Alan Fisher, Patrick William Strane, Lance Michael Black
  • Patent number: 11433068
    Abstract: This disclosure provides compositions and methods of treating cancer by inhibiting histone methyltransferases alone or in combination by synergistically inhibiting a histone demethylase, or a histone deacetylase (HDAC), or a bromodomain (BRD)-containing protein, or a B-Raf kinase. In particular, the cancers have deficient of SWI/SNF chromatin remodeling complexes because of mutations in one or more of the complex's subunit members.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: September 6, 2022
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: David E. Fisher, Qing Yu Weng, Shinichiro Kato
  • Publication number: 20220265914
    Abstract: A negative pressure therapy system is provided for inducing negative pressure in a portion of a urinary tract, the system including: (a) at least one ureteral catheter configured to be positioned within a ureter and/or kidney; (b) one or more sensor(s) configured to determine information about at least one of blood composition, blood flow, respiration, heart rate, glucose, protein, or creatinine; and (c) a controller configured to increase urine production by adjusting one or more operating parameters of a negative pressure source for inducing negative pressure through the at least one ureteral catheter into the urinary tract, based at least in part upon the information determined by the one or more sensor(s).
    Type: Application
    Filed: May 6, 2022
    Publication date: August 25, 2022
    Inventors: John R. Erbey, II, Jacob L. Upperco, Michael Alan Fisher, Patrick William Strane, Lance Michael Black, David E. Orr
  • Publication number: 20220202827
    Abstract: Compositions and methods for stimulating proliferation and/or migration of melanocytes in order to re-pigment skin regions, using ROCK inhibitors and optionally SIK inhibitors.
    Type: Application
    Filed: April 8, 2020
    Publication date: June 30, 2022
    Inventor: David E. Fisher
  • Publication number: 20220133736
    Abstract: The present disclosure provides methods of increasing skin pigmentation in a subject in need thereof using salt-inducible kinase (SIK) inhibitors, such as macrocyclic compounds of Formula (I), bicyclic urea compounds of Formula (II), (III), and (IV), and compounds of Formula (V), (VI), (VI-A), or (VII). Also provided are pharmaceutical compositions, methods, and uses that include or involve a compound described herein.
    Type: Application
    Filed: November 22, 2021
    Publication date: May 5, 2022
    Applicants: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: David E. Fisher, Nisma Mujahid, Ryo Murakami, Nathanael S. Gray, Yanke Liang, Hwan Geun Choi
  • Patent number: 11285158
    Abstract: The present disclosure provides methods of increasing skin pigmentation in a subject in need thereof using salt-inducible kinase (SIK) inhibitors, such as macrocyclic compounds of Formula (I), bicyclic urea compounds of Formula (II), (III), and (IV), and compounds of Formula (V), (VI), (VI-A), or (VII). Also provided are pharmaceutical compositions, methods, and uses that include or involve a compound described herein.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: March 29, 2022
    Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: David E. Fisher, Nisma Mujahid, Ryo Murakami, Nathanael S. Gray, Yanke Liang, Hwan Geun Choi
  • Patent number: 11045520
    Abstract: Described herein are compositions comprising, and methods for using a composition comprising, Staphylococcal Exfoliative Toxin A (ETA) in an amount and duration sufficient to decrease the Stratum Corneum in a region of a subjects skin.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: June 29, 2021
    Assignee: The General Hospital Corporation
    Inventors: Thanh-Nga Tran, David E. Fisher, Eric Boyer, Chong-Hyun Won
  • Publication number: 20210147425
    Abstract: The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind C protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
    Type: Application
    Filed: November 20, 2020
    Publication date: May 20, 2021
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Nathanael S. Gray, Yanke Liang, Hwan Geun Choi, Thomas Sundberg, Alykhan Shamji, Ramnik Xavier, David E. Fisher, Nisma Mujahid
  • Patent number: 10954242
    Abstract: The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: March 23, 2021
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Nathanael S. Gray, Yanke Liang, Hwan Geun Choi, Thomas Sundberg, Alykhan Shamji, Ramnik Xavier, David E. Fisher, Nisma Mujahid
  • Publication number: 20200317675
    Abstract: The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
    Type: Application
    Filed: July 5, 2017
    Publication date: October 8, 2020
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Nathanael S. GRAY, Yanke LIANG, Hwan Geun CHOI, Thomas SUNDBERG, Alykhan SHAMJI, Ramnik XAVIER, David E. FISHER, Nisma MUJAHID
  • Publication number: 20200253981
    Abstract: The present disclosure provides methods of increasing skin pigmentation in a subject in need thereof using salt-inducible kinase (SIK) inhibitors, such as macrocyclic compounds of Formula (I), bicyclic urea compounds of Formula (II), (III), and (IV), and compounds of Formula (V), (VI), (VI-A), or (VII). Also provided are pharmaceutical compositions, methods, and uses that include or involve a compound described herein.
    Type: Application
    Filed: February 28, 2018
    Publication date: August 13, 2020
    Applicants: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: David E. Fisher, Nisma Mujahid, Ryo Murakami, Nathanael S. Gray, Yanke Liang, Hwan Geun Choi
  • Patent number: 10653355
    Abstract: A system for visualizing melanin present in tissue can include an imaging system to record a signal based on a presence of melanin in tissue and a display device to display an image based on the signal. A first laser source can emit a Stokes pulse train and a second laser source can emit a pump pulse train. Both the first laser source and the second laser source comprise a tunable center wavelength or frequency. An energy difference between a frequency of the Stokes pulse train and a frequency of the pump pulse train is from 1750 cm?1 to 2250 cm?1. The Stokes and the pump pulse train overlap in space and time. A scanning mechanism focuses the combined Stokes pulse train and pump pulse train within the tissue and scans across the tissue. A detector detects the signal based on a presence of melanin within the tissue.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: May 19, 2020
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Hequn Wang, Conor L. Evans, Sam Osseiran, David E. Fisher
  • Publication number: 20190315752
    Abstract: The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
    Type: Application
    Filed: July 5, 2017
    Publication date: October 17, 2019
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Nathanael S. GRAY, Yanke LIANG, Hwan Geun CHOI, Thomas SUNDBERG, Alykhan SHAMJI, Ramnik XAVIER, David E. FISHER, Nisma MUJAHID
  • Publication number: 20190201396
    Abstract: This disclosure provides compositions and methods of treating cancer by inhibiting histone methyltransferases alone or in combination by synergistically inhibiting a histone demethylase, or a histone deacetylase (HDAC), or a bromodomain (BRD)-containing protein, or a B-Raf kinase. In particular, the cancers have deficient of SWUSNF chromatin remodeling complexes because of mutations in one or more of the complex's subunit members.
    Type: Application
    Filed: September 7, 2017
    Publication date: July 4, 2019
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: David E. FISHER, Qing Yu WENG, Shinichiro KATO
  • Publication number: 20190167561
    Abstract: This disclosure relates to methods of reducing or inhibiting the graying of hair by topically applying various cosmetic formulations to hair follicles and/or to the skin overlying hair follicles. The formulations applied in these methods include green tea extract and one or more additional plant extracts, in addition to one or more cosmetically acceptable carriers and/or accessory ingredients.
    Type: Application
    Filed: August 11, 2017
    Publication date: June 6, 2019
    Inventors: Ana Paula Pedroso Oliveira, Gabriela Placoná Diniz, Juliana Carvalhães Lago, Kelen Fabiola Arroteia, David E. Fisher
  • Publication number: 20190117727
    Abstract: Described herein are compositions comprising, and methods for using a composition comprising, Staphylococcal Exfoliative Toxin A (ETA) in an amount and duration sufficient to decrease the Stratum Corneum in a region of a subjects skin.
    Type: Application
    Filed: March 22, 2017
    Publication date: April 25, 2019
    Applicant: The General Hospital Corporation
    Inventors: Thanh-Nga Tran, David E. Fisher, Eric Boyer, Chong-Hyun Won
  • Publication number: 20190083455
    Abstract: Methods and compositions for treatment of pain, mood, or for the treatment of opiate withdrawal symptoms with the modulation of systemic beta-endorphin levels by the topical administration of cAMP elevating agents and/or dermal exposure to ultraviolet (UV) irradiation.
    Type: Application
    Filed: November 27, 2018
    Publication date: March 21, 2019
    Inventors: David E. Fisher, Kathleen Robinson, Gillian Fell, Rosa Veguilla
  • Publication number: 20180311505
    Abstract: Provided herein are methods that can be used to produce a local immune response in cancer tissue and/or enhance effectiveness of cancer treatment in a subject through application of one or more combinations of: an ablative fractional laser procedure, a checkpoint inhibitor, and an endosomal TLR agonist (e.g., a TLR3, TLR7, TLR8 or TLR9 agonist).
    Type: Application
    Filed: November 3, 2016
    Publication date: November 1, 2018
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: David E. FISHER, Jennifer A. LO, Dieter MANSTEIN, Masayoshi KAWAKUBO